- Home
- IMMX vs MYND Comparison
IMMX vs MYND Comparison
Compare IMMX & MYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- MYND
- Stock Information
- Founded
- IMMX 2014
- MYND 1998
- Country
- IMMX United States
- MYND Cayman Islands
- Employees
- IMMX N/A
- MYND N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- MYND Other Consumer Services
- Sector
- IMMX Health Care
- MYND Real Estate
- Exchange
- IMMX Nasdaq
- MYND Nasdaq
- Market Cap
- IMMX 61.1M
- MYND 85.8M
- IPO Year
- IMMX 2021
- MYND 2017
- Fundamental
- Price
- IMMX $2.17
- MYND $1.88
- Analyst Decision
- IMMX Strong Buy
- MYND
- Analyst Count
- IMMX 1
- MYND 0
- Target Price
- IMMX $7.00
- MYND N/A
- AVG Volume (30 Days)
- IMMX 269.5K
- MYND 118.6K
- Earning Date
- IMMX 11-12-2024
- MYND 02-05-2025
- Dividend Yield
- IMMX N/A
- MYND N/A
- EPS Growth
- IMMX N/A
- MYND N/A
- EPS
- IMMX N/A
- MYND N/A
- Revenue
- IMMX N/A
- MYND $357,050,000.00
- Revenue This Year
- IMMX N/A
- MYND N/A
- Revenue Next Year
- IMMX $200.00
- MYND N/A
- P/E Ratio
- IMMX N/A
- MYND N/A
- Revenue Growth
- IMMX N/A
- MYND N/A
- 52 Week Low
- IMMX $1.26
- MYND $0.61
- 52 Week High
- IMMX $7.50
- MYND $6.95
- Technical
- Relative Strength Index (RSI)
- IMMX 53.37
- MYND 47.68
- Support Level
- IMMX $1.88
- MYND $1.65
- Resistance Level
- IMMX $2.44
- MYND $2.60
- Average True Range (ATR)
- IMMX 0.32
- MYND 0.30
- MACD
- IMMX -0.02
- MYND -0.09
- Stochastic Oscillator
- IMMX 34.94
- MYND 21.91
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About MYND Mynd.ai Inc.
Mynd.ai Inc is a company that provides a platform for delivering digital content in K-12 classrooms, giving teachers seamless connectivity to inspire young minds. It features agnostic hardware that integrates across technology providers. Its product line includes a wide range of interactive tools and technologies, with its award-winning interactive displays at the forefront. It also offers interactive software apps such as Screen Share, computing modules, and accessories that meet the needs of customers, including K -12 educators, colleges and universities, small businesses and corporations, government agencies, and more.